Verrica Pharmaceuticals Inc (OQ:VRCA)

Sector:  Healthcare Industry:  Pharmaceuticals
 
See Regulatory Filings on SEC
Company Contact
Address: 10 N High St Ste 200
WEST CHESTER PA 19380-3014
Tel: N/A
Website: www.verrica.com
IR: See website
<
Key People
Paul B. Manning
Chairman of the Board
Ted W. White
President, Chief Executive Officer, Director
Brian Davis
Chief Financial Officer
Joe Bonaccorso
Chief Commercial Officer
Patrick Burnett
Chief Medical Officer
 
Business Overview
Verrica Pharmaceuticals Inc. is a United States-based clinical-stage medical dermatology company. The Company is focused on identifying, developing and commercializing pharmaceutical products for the treatment of skin diseases with unmet needs. Its lead product candidate, VP-102, is a drug-device combination of topical solution of cantharidin. The Company also intends to develop second cantharidin-based product candidate, VP-103, for the treatment of plantar warts. The Company has completed one Phase II clinical trial of topical solution of cantharidin administered with the wooden stick part of a cotton-tipped swab. It also conducting another Phase II clinical trial of topical solution of cantharidin administered through applicator, which collectively refer to as VP-102, for the treatment of molluscum.
Financial Overview
For the three months ended 31 March 2020, Verrica Pharmaceuticals Inc revenues was not reported. Net loss increased 31% to $9.8M. Higher net loss reflects General and administrative - Balancing v increase of 44% to $4.2M (expense), Research and development - Balancing val increase of 8% to $4.7M (expense), Interest income decrease of 49% to $278K (income).
Employees: 17 as of Dec 31, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $233.63M as of Mar 31, 2020
Annual revenue (TTM): $0.00M as of Mar 31, 2020
EBITDA (TTM): -$31.87M as of Mar 31, 2020
Net annual income (TTM): -$30.55M as of Mar 31, 2020
Free cash flow (TTM): -$29.78M as of Mar 31, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 25,814,493 as of May 4, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization